| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Filing example | Pre-clinical | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
IND Filing example | Pre-clinical | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
IND Filing example | Pre-clinical | — | Subscribe to access the data. | Biologics | Dermatologic System |
Recent Updates
Recently added Catalysts
Immunocore Holdings plc$33.77
-1.23 (-3.51%)
C 55Pipeline Score Overvalued Biotech · Commercial
Market Cap
1.47 B
EPS
-0.55
P/E Ratio
-
Value Trade
18.56 M
SEC Financials
Q1 2026Dilution Risk
Revenue
106.68 M
R&D Expenses
61.11 M
Operating CF
-13.78 M
Total Assets
1.07 B
Total Liabilities
678.42 M
Equity
393.67 M
D/E Ratio
12,345
0.35 %
Week
-2.4 %
1 Month
-13.24 %
3 Month
-25.98 %
6 Month
-22.35 %
5 Year
-29.68 %
All Time
Cash Data
Cash Position
844.90 M
Monthly Burn
4.59 M
Runway
181.3 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
329.11 K
52 Week Range
27.56 - 40.71
% held by Insiders
0.96 %
% held by Institutions
102.48 %
Enterprise Value
1.06 B
Total Shares
50.83 M
Short %
17.76 %
Float Shares
50.34 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immunocore Holdings plc
470Total events
9Upcoming
93Tier-1 (high impact)
2020 – 2028Coverage
Upcoming catalysts 2
TBD
T1Full Results
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
◆Topline ReadoutTebentafusp-TebnClinical Data
Subscribe to view catalyst details
TBD
◆Oral PresentationBrenetafuspPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-12-31 | IMC-M113V | Phase 1 data readout | Phase 1 | — | – | – | – |
2024-12-31 | IMC-M113V | Phase 1 data readout | Phase 1 | — | – | – | – |
2024-12-31 | IMC-M113V | Phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
C55
Pipeline Score $747M
Pipeline ValueOvervalued
Valuation Signal7
Drugs Scored0.5x
rNPV / MCap Top 85%
Micro Cap (rank 138 of 913)
Percentile RankImmunocore Holdings plc carries a moderate pipeline score (55/100), with $1.9B risk-adjusted pipeline value, led by Brenetafusp in Select Advanced Solid Tumors (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brenetafusp Small molecule | Advanced Melanoma | Phase 3 | NCT06112314 | 46% | $733M | RECRUITING | 680 | STALLED | B (65) | Oct 16, 2027 | HIGH_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
brenetafusp | heavily pretreated advanced melanoma | Phase 1/2 | 2026-05-31 | overall survival rate 6 months: 87%; disease control rate: 52%; median overall survival: 14.3 months; overall response rate: 12%; median overall survival primary PD1 resistance: 14.7 months; ct DNA response primary PD1 resistance: 53%; ct DNA response overall group: 38% Read More | Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Read More | |
brenetafusp | heavily pretreated advanced melanoma | Phase 1/2 | 2026-05-31 | overall survival rate 6 months: 87%; disease control rate: 52%; median overall survival: 14.3 months; overall response rate: 12%; median overall survival primary PD1 resistance: 14.7 months; ct DNA response primary PD1 resistance: 53%; ct DNA response overall group: 38% Read More | Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Read More | |
brenetafusp | heavily pretreated advanced melanoma | Phase 1/2 | 2026-05-31 | overall survival rate 6 months: 87%; disease control rate: 52%; median overall survival: 14.3 months; overall response rate: 12%; median overall survival primary PD1 resistance: 14.7 months; ct DNA response primary PD1 resistance: 53%; ct DNA response overall group: 38% Read More | Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMCR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IMCR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IMCRImmunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore has presented updated Phase 1 data for brenetafusp, showing an 87% overall survival rate at 6 months in heavily pretreated advanced melanoma patients. The data supports the selection of a 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial. Brenetafusp demonstrated consistent clinical benefits across difficult-to-treat subgroups, including those with primary PD-1 resistance.
Read more →IMCR▲ +6.6%on this news
Immunocore reports first quarter financial results and provides a business update
Immunocore reported a strong financial performance for Q1 2026, with KIMMTRAK generating $106.7 million in net sales, a 14% increase from the previous year. The company highlighted significant survival data from a Phase 3 trial presented at AACR, marking a pivotal moment for KIMMTRAK in treating metastatic uveal melanoma. Immunocore continues to expand its pipeline and market presence, with ongoing trials and a robust cash position.
Read more →IMCRImmunocore to present at the 25th Annual Needham Virtual Healthcare Conference
Immunocore Holdings plc will present at the 25th Annual Needham Virtual Healthcare Conference, which is scheduled for April 13, 2026. The company, known for its innovative immunomodulating medicines, is leveraging its ImmTAX platform to develop treatments targeting cancer, autoimmune diseases, and infectious diseases. Attendees can access the live webcast of the presentation on Immunocore's website, which will also host a replay afterward.
Read more →IMCRImmunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Immunocore Holdings plc announced that it will present five-year overall survival data for KIMMTRAK at the 2026 AACR Annual Meeting. This data, derived from a Phase 3 trial in patients with metastatic uveal melanoma, represents the longest follow-up in a randomized trial for this condition. The presentation will also include additional data on subsequent treatments and prognostic factors.
Read more →IMCRImmunocore to present at upcoming investor conferences
Immunocore Holdings plc announced its participation in several upcoming investor conferences in March 2026. The events include presentations and discussions at notable healthcare conferences, showcasing the company's advancements in immunomodulating therapies. Immunocore's lead product, KIMMTRAK, is already approved for treating certain cancer patients, highlighting its commitment to innovative treatments.
Read more →IMCRImmunocore reports fourth quarter and full year 2025 financial results and provides a business update
Immunocore reported strong financial results for Q4 and full year 2025, with KIMMTRAK generating $400 million in sales. The company anticipates completing enrollment for TEBE-AM in 1H 2026 and presenting Phase 1/2 data for its PRAME franchise in 2H 2026. Despite the positive growth, revenue moderation is expected in 2026.
Read more →IMCRImmunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
Immunocore Holdings plc will report its fourth quarter and full year 2025 financial results on February 25, 2026. Following the announcement, a live teleconference will be held to discuss the results and provide updates on the company's business and portfolio. Immunocore is known for its innovative TCR bispecific immunotherapies, including the approved KIMMTRAK for certain cancer patients.
Read more →IMCRImmunocore announces R&D leadership evolution
Immunocore Holdings plc announced the departure of Dr. David Berman, Executive Vice President of R&D, effective February 27, 2026. In his place, Dr. Mohammed Dar and Mark Moyer have been promoted to Executive Vice President roles, enhancing their oversight of clinical development and regulatory strategies. The company aims to streamline its R&D structure while maintaining its focus on ongoing clinical programs.
Read more →IMCRImmunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
Immunocore has outlined its strategic priorities for 2026 at the J.P. Morgan Healthcare Conference, focusing on expanding its melanoma franchise with KIMMTRAK and enrolling in three Phase 3 trials. The company anticipates presenting Phase 1/2 data for its PRAME franchise and initiating a Phase 1 trial for type 1 diabetes. With a strong cash position, Immunocore aims to address high unmet needs in oncology and autoimmune diseases.
Read more →IMCR▲ +6%on this newsshared move
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
Immunocore presented Phase 1 trial data for IMC-I109V, a bispecific T cell receptor targeting hepatitis B. The trial demonstrated a manageable safety profile and antiviral activity, with dose-dependent reductions in HBsAg levels. The findings support further investigation of this novel therapy for chronic HBV infection.
Read more →IMCRImmunocore reports third quarter financial results and provides a business update
Immunocore reported a strong third quarter for 2025, with KIMMTRAK net revenues reaching $103.7 million, a 29% increase year-over-year. The company is on track with its Phase 3 trials, including the TEBE-AM trial, expected to complete enrollment in the first half of 2026. Despite a net loss this quarter, Immunocore maintains a robust cash position of $892 million.
Read more →IMCRImmunocore reports second quarter financial results and provides a business update KIMMTRAK (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to com
Immunocore has reported strong financial results for the second quarter of 2025, with KIMMTRAK generating net revenues of $98 million, a 30% increase year-over-year. The company is on track with its Phase 3 TEBE-AM trial, expected to complete enrollment in the first half of 2026, alongside advancements in other trials. Immunocore's cash reserves stood at $883 million, supporting its ongoing research and development efforts despite a net loss of $10.3 million during the quarter. The company continues to focus on expanding its product reach globally and diversifying its pipeline.
Read more →IMCRImmunocore to report second quarter 2025 financial results and host call on August 7, 2025
Immunocore Holdings plc will report its second quarter financial results on August 7, 2025, before US markets open. Following the announcement, a live teleconference will be held to discuss the results and provide updates on the company's business and portfolio. Immunocore is known for its innovative TCR bispecific immunotherapies, including KIMMTRAK, which is approved for certain cancer treatments.
Read more →IMCR▲ +5.6%on this news
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
Immunocore Holdings plc announced its participation in the 2025 Jefferies Global Healthcare Conference, scheduled for June 5, 2025. The event will feature a live webcast of the presentation, which can be accessed through the company's website. Immunocore focuses on developing TCR bispecific immunotherapies to treat cancer and other diseases, with its leading product, KIMMTRAK, already approved in several regions.
Read more →IMCR▲ +6.6%on this news
Immunocore reports first quarter financial results and provides a business update KIMMTRAK (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to
Immunocore announced strong first quarter financial results for 2025, reporting KIMMTRAK net revenues of $93.9 million, up 33% from the previous year. The company also highlighted a shift from a net loss to a net income of $5.0 million. With a robust pipeline, Immunocore remains focused on its ongoing trials, including the Phase 3 TEBE-AM trial and the PRISM-MEL-301 trial. The firm maintains a favorable cash position of $837 million, supporting further development and commercialization of its innovative therapies.
Read more →IMCRImmunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
Immunocore presented initial data from the Phase 1/2 STRIVE trial for IMC-M113V, a candidate for HIV functional cure, at CROI 2025. The therapy was well tolerated, with no serious adverse events reported. Initial results indicate dose-dependent viral control following antiretroviral treatment interruption. The trial continues to evaluate higher doses.
Read more →IMCR▲ +5.3%on this newsshared move
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected
Immunocore Holdings plc reported a strong performance for the fourth quarter and full year 2024, with KIMMTRAK net sales reaching $84.1 million and $310.0 million, respectively. The company has executed a robust lifecycle management program for KIMMTRAK and is conducting multiple Phase 3 and Phase 1 trials to expand its clinical portfolio. Despite continued revenue growth, Immunocore reported a net loss of $51.1 million for the year, alongside increasing R&D and SG&A expenses. The company maintains a solid cash position, which is expected to support ongoing and future clinical developments.
Read more →IMCRImmunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
Immunocore Holdings plc will report its financial results for the fourth quarter and full year 2024 on February 26, 2025. Following the announcement, the company will host a teleconference to discuss these results and provide an update on its business and portfolio. Immunocore continues to develop innovative therapies through its ImmTAX platform, with KIMMTRAK already approved for specific cancer treatments. The company is navigating forward-looking statements regarding its clinical pipeline and future growth.
Read more →IMCRImmunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Immunocore Holdings has outlined its strategic priorities for 2025, focusing on enhancing patient access to KIMMTRAK for metastatic uveal melanoma and advancing its oncology pipeline with three Phase 3 trials. The company also aims to innovate in autoimmune therapies, with plans to submit clinical trial applications for two candidates targeting Type 1 diabetes and atopic dermatitis. CEO Bahija Jallal discussed the company's commitment to addressing high unmet medical needs and expanding its clinical portfolio in oncology and infectious diseases. The updates will be presented at the 43rd Annual J.P. Morgan Healthcare Conference.
Read more →IMCRImmunocore announces strategic priorities at 43 rd Annual J.P. Morgan Healthcare Conference Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community pene
Immunocore Holdings plc has outlined its strategic priorities for 2025 during the 43rd Annual J.P. Morgan Healthcare Conference. The company aims to expand the global reach of its melanoma therapy KIMMTRAK and enroll patients in three Phase 3 trials, with topline results anticipated in 2026. Additionally, Immunocore is advancing various clinical trials across oncology and infectious diseases while introducing groundbreaking therapies for autoimmune conditions. The company maintains a solid financial foundation as it prepares for continued growth and innovation in immunotherapy.
Read more →IMCRImmunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
Immunocore Holdings plc is set to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2025. The live presentation will showcase the company's efforts in developing transformative immunotherapies, including their proprietary ImmTAX platform. Immunocore is advancing multiple clinical-stage programs in oncology and infectious diseases, highlighting their commitment to improving patient outcomes. The event will also be available for streaming on their website.
Read more →IMCRImmunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
Immunocore Holdings has appointed Travis Coy as its Executive Vice President, Chief Financial Officer, and Head of Corporate Development, effective January 1, 2025. Coy transitions from a Non-Executive Director role he held since September 2019 and brings over 20 years of experience from Eli Lilly. His leadership is anticipated to be instrumental in advancing Immunocore's mission to deliver innovative therapies for cancer and autoimmune diseases, leveraging its ImmTAX immunotherapy platform.
Read more →IMCRImmunocore appoints Travi s Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development ( OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US , 02 Januar
Immunocore appoints Travi s Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development ( OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US , 02 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore"
Read more →IMCRImmunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Immunocore has announced the dosing of the first patient in its Phase 1 trial for IMC-P115C, a half-life extended ImmTAC candidate targeting tumors expressing PRAME. This trial aims to evaluate the safety and clinical efficacy in HLA-A*02:01-positive patients with advanced solid tumors. IMC-P115C represents an advancement over previous treatments, as it reduces the frequency of administration, potentially improving patient compliance and treatment outcomes. This trial is significant for the ongoing development of Immunocore's bispecific protein therapies, contributing to the understanding of PRAME-targeted treatments in oncology.
Read more →IMCRImmunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
Immunocore Holdings plc has announced the treatment of the first patient in the Phase 1/2 trial for its candidate IMC-R117C, which targets the PIWIL1 antigen in patients with advanced gastrointestinal cancers. This trial aims to evaluate both the safety and efficacy of IMC-R117C as a monotherapy and in combination with standard therapies. PIWIL1 is associated with several aggressive cancer types, including colorectal cancer, highlighting the need for novel treatment options. The company believes that this immunotherapy could significantly benefit patients who are refractory to existing treatments.
Read more →IMCRImmunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Immunocore Holdings plc announced that its drug KIMMTRAK (tebentafusp) has been recommended for funding by the National Institute for Health and Care Excellence (NICE) for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. This decision marks a significant shift from a previous negative recommendation in May 2023, which the company successfully appealed. The approval offers hope to patients suffering from this rare and aggressive cancer, allowing them access to the first therapy shown to improve survival outcomes. The decision highlights the importance of medical collaboration in advancing patient care.
Read more →IMCRImmunocore reports third quarter financial results and provides a business update KIMMTRAK (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing
Immunocore Holdings plc reported third quarter financial results showing net revenues of $80.2 million, a 28% increase compared to the same quarter last year. The company continues to advance its pipeline, with ongoing Phase 3 trials for KIMMTRAK and planned trials for brenetafusp and other candidates. Immunocore's positive earnings per share reflect strong performance, although R&D costs have risen significantly. The company also faces management changes as the CFO plans to depart, which may affect future strategic decisions.
Read more →IMCRImmunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily pre-t
Immunocore Holdings plc presented Phase 1 data for brenetafusp at the 2024 ESMO Congress, demonstrating its clinical activity as a monotherapy and in combination with chemotherapy in heavily pre-treated platinum-resistant ovarian cancer patients. Data showed a 58% disease control rate for monotherapy and a 69% disease control rate for the combination treatment, significantly improving on historical chemotherapy outcomes. Safety profiles were consistent, with manageable cytokine release syndrome as the most common adverse effect. The findings support further exploration of brenetafusp in earlier treatment lines.
Read more →IMCRImmunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Immunocore Holdings presented Phase 1 data for brenetafusp at the ESMO Congress, highlighting its activity in platinum-resistant ovarian cancer patients. The data suggest that brenetafusp can be used alone or in combination with chemotherapy, demonstrating significant disease control and a favorable safety profile. A total of 37 patients received the monotherapy, and results indicated a median progression-free survival of 3.3 months. While the findings are promising, the overall survival data is not yet conclusive, urging further exploration in upcoming trials.
Read more →IMCRImmunocore to present at the 2024 Cantor Global Healthcare Conference
Immunocore Holdings plc has announced its participation in the 2024 Cantor Global Healthcare Conference, scheduled for September 19, 2024. The presentation will focus on the company’s advancements in TCR bispecific immunotherapies, particularly its ImmTAX platform. Immunocore's flagship product, KIMMTRAK, has already gained approval for treating unresectable or metastatic uveal melanoma. The event will be accessible via a live webcast from Immunocore's website, with a replay available afterward.
Read more →IMCRImmunocore announces transition of Chief Financial Officer ( OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US , 29 August 2024) Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company") , a co
Immunocore Holdings plc has announced the impending departure of its Chief Financial Officer, Brian Di Donato, who will leave at the end of the year to become CEO of a private biotech company in San Diego. Di Donato will remain with Immunocore through the end of 2024 to ensure a smooth transition, during which the company will search for his successor. His leadership has been credited with significant achievements, including the successful IPO and capital raising efforts. Immunocore continues to develop innovative immunotherapies and has several ongoing clinical trials in its pipeline.
Read more →IMCRImmunocore reports second quarter financial results and provides a business update KIMMTRAK (tebentafusp-tebn) net revenues of $75.3 million in 2Q 2024 driven by US growth Registrational Phase 3 TEBE-AM trial with KIMMTR
Immunocore has reported financial results for the second quarter of 2024, highlighting a significant increase in net revenues for KIMMTRAK, which reached $75.3 million. The company is currently conducting multiple Phase 3 trials, with expectations for registrational data in 2026, 2027, and 2028. Despite an increase in research and development expenditures, improvements in financial losses were noted compared to the previous year.
Read more →IMCRImmunocore to report second quarter 2024 financial results and host call on August 8, 2024
Immunocore Holdings plc plans to release its second quarter 2024 financial results on August 8, 2024, prior to market opening. Following the results announcement, the company will host a teleconference to discuss the financial outcomes and provide updates on their business and portfolio. Immunocore is noted for its development of TCR bispecific immunotherapies, with KIMMTRAK being a notable treatment that has received approval in various territories.
Read more →IMCRImmunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
Immunocore has randomized the first patient in the global Phase 3 PRISM-MEL-301 trial to evaluate brenetafusp for advanced cutaneous melanoma. This trial is unique as it is the first registrational study investigating a PRAME-targeted therapy in combination with nivolumab. The primary endpoint focuses on progression-free survival, with additional insights from recent encouraging monotherapy results during ASCO 2024. The trial's findings could represent a significant advancement in treatment options for patients with metastatic melanoma.
Read more →IMCR▼ -12.7%on this news
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
Immunocore Holdings plc presented new KIMMTRAK clinical data at the ASCO 2024 Annual Meeting, indicating that patients with stable disease and confirmed tumor reductions exhibited similar clinical outcomes to those with partial responses. This data reinforces KIMMTRAK's effectiveness as the standard treatment for HLA-A*02:01-positive patients with unresectable or metastatic uveal melanoma. Additionally, the findings suggest that doctors can confidently discuss treatment benefits with patients experiencing stable disease. While the treatment shows promise, it is important to monitor for potential serious side effects.
Read more →IMCRImmunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy brenetafusp (IMC-F106C) in l
Immunocore has released updated Phase 1 data on brenetafusp (IMC-F106C), showing promising results in patients with late-line cutaneous melanoma previously treated with immune checkpoint inhibitors. The therapy demonstrated a 58% disease control rate among PRAME positive patients and was well tolerated with manageable side effects. Immunocore is currently conducting a Phase 3 clinical trial of brenetafusp in combination with nivolumab in first-line advanced cutaneous melanoma, aiming to further evaluate its efficacy. The data highlights the potential of brenetafusp as a significant treatment option for this patient population.
Read more →IMCRImmunocore to present at the Jefferies Global Healthcare Conference
Immunocore Holdings plc announced its participation in the upcoming Jefferies Global Healthcare Conference, scheduled for June 6, 2024. The event will include a presentation that will be broadcast live online. Immunocore is known for its innovative TCR bispecific immunotherapies aimed at treating various diseases, including cancer and autoimmune disorders. The company has an extensive clinical pipeline and has achieved regulatory approvals for its lead therapy, KIMMTRAK.
Read more →IMCRImmunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA, all patients randomize
Immunocore Holdings plc has announced the conversion of its TEBE-AM Phase 2/3 clinical trial into a registrational Phase 3 trial for KIMMTRAK, targeted at previously treated advanced cutaneous melanoma. Following an FDA consultation, all patients from the initial Phase 2/3 trial will now be included in the Phase 3 trial's intent-to-treat population. The Phase 3 trial will evaluate KIMMTRAK both as a monotherapy and in combination with pembrolizumab, aiming to enhance overall survival outcomes. This decision underscores KIMMTRAK's promising efficacy observed in earlier trials with metastatic melanoma patients.
Read more →IMCRImmunocore reports first quarter financial results and provides a business update KIMMTRAK (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since
Immunocore Holdings plc reported a strong financial performance for Q1 2024, with KIMMTRAK net revenues reaching $70.3 million, reflecting a 36% year-over-year increase. The company continues to broaden its global market presence with seven new product launches and is making advancements in its clinical pipeline, notably with brenetafusp highlighting promising data set for presentation at upcoming conferences. However, Immunocore also reported a higher net loss compared to the previous year, driven by escalating research and development costs.
Read more →IMCRImmunocore announces upcoming presentation and posters at ASCO 2024
Immunocore Holdings plc is set to present key data at the ASCO 2024 Annual Meeting starting on May 31. The company will showcase Phase 1 expansion data for brenetafusp (IMC-F106C), emphasizing its potential effectiveness in treating cutaneous melanoma patients previously treated with anti-PD1. Additionally, four posters will be presented, including updates from the Phase 3 PRISM-MEL301 trial and data on various aspects related to KIMMTRAK in metastatic uveal melanoma. An investor event will accompany the presentations, focusing on the company's future developments.
Read more →IMCRImmunocore presented two posters at CROI 2024
Immunocore Holdings plc presented two posters at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) that highlighted its innovative research in HIV treatment. One poster focused on the implications of TCR biology in developing new therapies, while the other addressed the instability of the HLA-E peptidome as a barrier to therapeutic targeting. The company continues to advance its ImmTAV molecules aimed at curing HIV and hepatitis B virus (HBV). This research reflects Immunocore's commitment to improve outcomes for patients with infectious diseases.
Read more →IMCRImmunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023; increasing commercial acce
Immunocore Holdings has announced its financial results for Q4 2023, reporting KIMMTRAK revenue of $67.6 million and a total of $238.7 million for the year. The company aims to broaden KIMMTRAK's market presence globally, launching in Australia and Canada, while pursuing multiple new clinical trials. Significant clinical collaborations, including with Bristol Myers Squibb, are underway. Although Immunocore faces increasing operating losses, its cash reserves remain strong, indicating a stable position for future growth in oncology and immunotherapy.
Read more →IMCRImmunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
Immunocore Holdings plc has announced a collaboration with Bristol Myers Squibb to evaluate the combination of its bispecific TCR candidate IMC-F106C with nivolumab in a Phase 3 clinical trial for first-line advanced cutaneous melanoma. The trial, named PRISM-MEL-301, will assess the efficacy of this combination in HLA-A*02:01 positive patients compared to control groups. Immunocore will fund the trial while Bristol Myers Squibb will supply nivolumab. The first patient is expected to be randomized in the first quarter of 2024.
Read more →IMCRImmunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
Immunocore Holdings plc has announced that it will report its fourth quarter and full year 2023 financial results on February 28, 2024. This will be followed by a live teleconference and webcast discussing the financial outcomes and providing a business update. The company emphasizes its role in delivering transformative immunotherapies and highlights a robust pipeline in various therapeutic areas. Interested parties can access the webcast through the company's website and will also have the option to view a replay afterward.
Read more →IMCR▼ -6.2%on this news
Immunocore Prices Upsized Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md
Immunocore Holdings plc has announced the pricing of an upsized $350 million offering of 2.50% convertible senior notes due 2030. The offering is aimed at qualified institutional buyers and is expected to close on February 2, 2024. The funds will be used to enhance the company's clinical pipeline, repay outstanding loans, and for general corporate purposes. The notes will accrue interest semi-annually and can be converted into American Depositary Shares at an initial conversion rate equivalent to roughly 40% above the current market price of the shares.
Read more →IMCRImmunocore Announces Proposed Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md
Immunocore Holdings plc has announced its intent to offer $300 million of convertible senior notes due in 2030, with an option for an additional $45 million. The net proceeds from this offering are intended to accelerate its clinical pipeline and support ongoing commercial expansion. However, the offering is subject to market conditions, and its final terms are yet to be determined. Immunocore's success in meeting its expectations from this offering remains uncertain.
Read more →IMCRImmunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
Immunocore Holdings plc has announced its strategic priorities and pipeline expansion ahead of the 42nd Annual J.P. Morgan Healthcare Conference. The company aims to enhance the global rollout of its therapy KIMMTRAK, pursue two registrational trials in advanced cutaneous melanoma, and advance new ImmTAC candidates targeting various cancers. Additionally, Immunocore plans to expand its focus into autoimmune diseases with the introduction of two new candidates. Key clinical readouts are anticipated in 2024, demonstrating progress in both oncology and infectious diseases.
Read more →IMCRImmunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
Immunocore Holdings plc will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The company, known for its innovative immunomodulating medicines, will showcase its advancements in treating cancer, autoimmune diseases, and infectious diseases. The event will be webcast live on Immunocore's website and will feature updates on their therapeutic pipeline, including their approved oncology treatment KIMMTRAK.
Read more →IMCRImmunocore announces strategic priorities and pipeline expansion ahead of 42 nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to KIMMTRAK (tebentafusp-tebn) globally, and pursuing fut
Immunocore has announced its strategic priorities and pipeline expansion in anticipation of the upcoming 42nd Annual J.P. Morgan Healthcare Conference. The company aims to increase global access to its therapy KIMMTRAK while pursuing new growth opportunities, including two registrational trials in advanced melanoma. Furthermore, Immunocore is advancing several ImmTAC candidates and has added new bispecific treatments targeted at autoimmune diseases to its arsenal. Expecting multiple clinical readouts throughout 2024, the company is poised to engage further in various therapeutic areas.
Read more →IMCR▲ +5.7%on this news
Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements Unaudited Condensed Consolidated Statements of Profit / (Loss) and Comprehensive (Loss) / Income Three Months Ended September 30, Nine
Immunocore Holdings plc has released its unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2023. The results indicate a substantial increase in product revenue, but the company also reported significant losses. While cash and total assets showed growth, the rise in operating losses and comprehensive losses raises concerns about the company's financial health. Overall, the financial performance reflects a mixed outlook as it continues to invest heavily in research and development.
Read more →IMCR▲ +5.7%on this news
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
Immunocore Holdings plc reported solid financial results for Q3 2023, with net revenues for KIMMTRAK reaching £49.7 million, showing a 9% increase from the previous quarter. The company announced a new Phase 3 trial in collaboration with the EORTC for KIMMTRAK as adjuvant therapy in uveal melanoma, along with promising long-term survival data published in the New England Journal of Medicine. Cash reserves rose to £364 million, ensuring support for ongoing and upcoming clinical trials. This demonstrates Immunocore's strong market presence and commitment to expanding its therapeutic offerings.
Read more →IMCRImmunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
Immunocore Holdings plc announced that it will present data for its therapy KIMMTRAK at the upcoming Society for Immunotherapy of Cancer Annual Meeting and the Society for Melanoma Research Congress. A total of seven posters will be showcased, covering various aspects of metastatic uveal melanoma and cutaneous melanoma treatment. KIMMTRAK has demonstrated marked survival benefits in clinical trials, positioning it as a promising therapy in the field of oncology.
Read more →IMCRImmunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
Immunocore Holdings plc has presented three-year overall survival data from the KIMMTRAK Phase 3 trial, showing a notable survival advantage for HLA-A*02:01 positive patients with metastatic uveal melanoma. The trial indicated a 27% survival rate for patients on KIMMTRAK, compared to 18% in the control group. Additionally, KIMMTRAK exhibited early survival benefits within the first six weeks and consistent outcomes in overall response rates. The findings were shared at the ESMO Congress 2023 and published in the New England Journal of Medicine, supporting KIMMTRAK's position as first-line therapy in this patient population.
Read more →IMCRImmunocore announces upcoming presentation and posters at ESMO 2023
Immunocore Holdings plc announced the upcoming presentation of its three-year Phase 3 survival data for KIMMTRAK at the ESMO 2023 Congress. This data relates to previously untreated patients with metastatic uveal melanoma and will be presented in a late-breaking abstract session. Additionally, Immunocore will share three posters detailing the effects of subsequent therapies on KIMMTRAK treatment outcomes, the reprogramming effects on tumor-associated M2 macrophages, and the implications of BRAF mutation status on treatment efficacy.
Read more →IMCRImmunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
Immunocore Holdings plc reported a strong second quarter for 2023, with KIMMTRAK generating net revenues of £45.5 million. The company announced an upcoming Phase 3 trial for IMC-F106C aimed at treating first-line cutaneous melanoma, expected to commence by Q1 2024. Additionally, there was an increase in cash reserves to £342 million, reflecting robust financial health. Despite positive developments, a collaboration with Sanofi was terminated, and the final decision regarding the CMS Proposed Rule remains uncertain.
Read more →IMCRImmunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements Unaudited Condensed Consolidated Statements of Loss and Comprehensive Loss Three months ended June 30, Six Months Ended June 30, Notes
Immunocore Holdings plc reported its unaudited condensed consolidated interim financial statements for the six months ending June 30, 2023. The company experienced significant growth in product revenue, reaching nearly $45.5 million, a notable increase from $24 million in the same period last year. However, despite this revenue growth, Immunocore reported a net loss of $14.1 million, reflecting an increase in operating losses compared to the previous year. The accumulated deficit has also grown, indicating ongoing financial challenges despite increased revenues.
Read more →IMCRImmunocore to report second quarter 2023 financial results and host call on August 10, 2023
Immunocore Holdings Plc has announced that it will report its second quarter financial results on August 10, 2023. The company will host a live teleconference at 8:00 a.m. EDT to discuss these results and provide updates on its business and portfolio. Immunocore is recognized for its pioneering work in T cell receptor bispecific immunotherapies, including its advanced therapy KIMMTRAK for treating specific cancer patients.
Read more →IMCRImmunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival ( OXFORDSH
Immunocore Holdings plc presented new data at the ASCO meeting regarding their KIMMTRAK Phase 3 trial. The study highlights that early on-treatment ctDNA reduction is correlated with longer overall survival in patients with stable disease. The trial showcased impressive results, with a high majority of patients showing ctDNA reduction by week 9. However, it also noted significant safety concerns, including high rates of cytokine release syndrome and skin reactions among treated patients.
Read more →IMCRImmunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
Immunocore Holdings plc presented additional data on ctDNA from the KIMMTRAK Phase 3 trial at the ASCO 2023 meeting. The analysis indicated that early reduction of circulating tumor DNA in patients with stable disease was linked to longer overall survival. The findings validate ctDNA reduction as an early indicator of survival benefits in metastatic uveal melanoma, where KIMMTRAK has shown significant efficacy. The company also introduced a trial-in-progress poster for a Phase 2/3 trial exploring tiventafusp in combination with pembrolizumab for advanced melanoma.
Read more →IMCRImmunocore Reports First Quarter 2023 Financial Results and Provides Business Update
Immunocore Holdings plc reported its financial results for Q1 2023, revealing net revenues from KIMMTRAK of £42.1 million ($52.0 million), demonstrating continued commercial growth. KIMMTRAK has gained dominance as the leading therapy for HLA-A*02:01 positive metastatic uveal melanoma patients. The company has also initiated new clinical trials and is expanding its pipeline with novel therapies for various indications, including HIV. Despite increased research and development expenses, the company remains optimistic about future growth and market expansion.
Read more →IMCRImmunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements Unaudited Condensed Consolidated Statements of Loss and Other Comprehensive Income Three months ended March 31, Notes 2023 '000 2022 '
Immunocore Holdings plc reported its unaudited condensed consolidated financial results for the three months ended March 31, 2023. The company achieved a total revenue of £44,541,000, driven primarily by a notable increase in product revenue which reached £42,052,000. Despite the growth in revenue, Immunocore recorded an operating loss of £17,387,000, slightly higher than the previous year's loss of £16,460,000. Additionally, total comprehensive loss remained substantial at £16,317,000 due to increased costs.
Read more →IMCRImmunocore to present at the Bank of America Securities 2023 Health Care Conference
Immunocore Holdings Plc has announced its participation in the Bank of America Securities 2023 Health Care Conference. The presentation is scheduled for May 10, 2023, and will be accessible via webcast on the company's website. Immunocore focuses on T cell receptor bispecific immunotherapies, with several clinical programs and one approved therapy for uveal melanoma.
Read more →IMCRTHIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or the action you should take, you should immediately consult your stockbroker, bank manager,
Immunocore Holdings plc has announced the details for its 2023 Annual General Meeting (AGM), scheduled for May 16, 2023. The AGM will take place both in-person at Cooley (UK) LLP and virtually via an online platform. Shareholders are encouraged to submit proxy votes and are provided with background information on the resolutions to be voted on. The company emphasizes the importance of consulting professional advisers regarding the document's contents and any forward-looking statements made.
Read more →IMCRImmunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival In the Phase 3 trial, early on-treatment ctDNA reduction was strongly associated with longer overall
Immunocore has presented data at the 2023 AACR Annual Meeting that suggests early reduction of circulating tumor DNA (ctDNA) in patients treated with KIMMTRAK is strongly correlated with longer overall survival in metastatic uveal melanoma. A median follow-up of 46 months from a previous trial indicated a median overall survival of 16.8 months, nearly double historical rates for this condition. Additionally, KIMMTRAK's approval spans over 30 countries, highlighting its broad clinical application. Future updates from ongoing trials are anticipated later in 2023.
Read more →IMCRImmunocore to present at the 22nd Annual Needham Virtual Healthcare Conference
Immunocore Holdings Plc (Nasdaq: IMCR) announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, scheduled for April 17, 2023. The presentation will highlight its development of T cell receptor bispecific immunotherapies aimed at treating various diseases. Notably, the company's product KIMMTRAK has received approvals for treating HLA-A*02:01-positive adult patients with certain forms of melanoma. The event will be webcast live from Immunocore's website.
Read more →IMCRImmunocore to present four posters at AACR Annual Meeting 2023
Immunocore Holdings plc is set to present four posters at the upcoming AACR Annual Meeting 2023, showcasing updated data on its drug tebentafusp for metastatic uveal melanoma. Key findings include evidence that early ctDNA reduction is linked to better overall survival outcomes in previously untreated patients. The presentations will highlight long-term survival follow-ups and responses in orbital lesions treated with the drug. Immunocore continues to advance its TCR bispecific immunotherapy platform, ImmTAX, indicating significant potential in oncology and other therapeutic areas.
Read more →IMCRFORWARD LOOKING STATEMENTS This letter contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "can," "will," "
Immunocore Holdings plc discusses its achievements and future prospects in a recent update. The company celebrates the approval of KIMMTRAK in over 30 countries and reports significant revenues in 2022. Immunocore aims to expand its product pipeline with new therapies targeting melanoma and infectious diseases. Additionally, they highlight ongoing clinical trials and the potential for their candidates to achieve regulatory approvals, despite facing market and operational challenges.
Read more →IMCRImmunocore Reports 2022 Financial Results and Provides Business Update KIMMTRAK / tebentafusp net revenues of 42 million ($51 million) in Q4 2022 and 117 million ($141 million) in 2022; approved in over 30 countries and
Immunocore has reported its financial results for Q4 2022 and the full year, highlighting KIMMTRAK's impressive net revenues of $142 million. The company continues to expand its clinical trials, including an upcoming IND for a novel therapy targeting PIWIL1. Despite its strong revenue performance and expanding international presence, Immunocore reported a net loss in 2022, reflecting increased expenses in research and development.
Read more →IMCRImmunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
Immunocore Holdings plc plans to report its full year 2022 earnings on March 1, 2023. The company will also host a live teleconference to discuss financial results and provide a business update. Immunocore specializes in T cell receptor bispecific immunotherapies targeting various diseases, including cancer and autoimmune diseases. The company's lead therapy, KIMMTRAK, has been approved to treat certain patients with metastatic uveal melanoma in several regions.
Read more →IMCRImmunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV Data from the single ascending dose part of the Phase 1 trial shows IMC-M113V is wel
Immunocore Holdings plc has announced initial results from a Phase 1 clinical trial of IMC-M113V, a novel soluble TCR therapy for HIV. The single ascending dose part of the trial demonstrated that the therapy was well tolerated, with no serious adverse events reported. Notably, half of the participants administered the 15-mcg dose exhibited markers consistent with T cell activation, suggesting potential efficacy. Further enrollment is underway for the multiple ascending dose part of the trial to continue assessing the therapy's safety and antiviral activity.
Read more →IMCRImmunocore announces strategic priorities including pipeline expansion for 2023 -2024 KIMMTRAK (tebentafusp-tebn) approved in over 30 countries with continued global expansion in 2023-2024; preliminary unaudited net sale
Immunocore has outlined its strategic priorities for 2023-2024, focusing on the expansion of its pipeline, including new ImmTAC candidates targeting various cancers. KIMMTRAK has been approved in over 30 countries, contributing to preliminary net sales of approximately $140 million for 2022. The company plans to enroll patients in ongoing clinical trials, including IMC-F106C, while also developing new therapies to address patient needs. Immunocore will present updates at the upcoming J.P. Morgan Healthcare Conference.
Read more →IMCR▼ -5.7%on this newsshared move
Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
Immunocore has announced its strategic priorities for 2023-2024, focusing on the expansion of its pipeline and ongoing clinical trials. The company reported preliminary unaudited net sales of approximately $140 million for 2022, with KIMMTRAK authorized in over 30 countries. Key priorities include advancing the IMC-F106C clinical trial and enhancing the PRAME franchise with new ImmTAC candidates. The company aims to present additional data, reflecting its commitment to innovative cancer treatments and global market expansion.
Read more →IMCRImmunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
Immunocore Holdings Plc announced its participation in the 41st Annual J.P. Morgan Healthcare Conference, scheduled for January 11, 2023. The company specializes in T cell receptor bispecific immunotherapies, including their advanced product KIMMTRAK, which is approved for treating certain types of melanoma. The presentation will be available via webcast and aims to showcase Immunocore's innovations and ongoing development in various therapeutic fields. This event indicates the company's active role in engaging with investors and the healthcare community.
Read more →IMCRImmunocore is awarded the Prix Galien France award for KIMMTRAK
Immunocore is awarded the Prix Galien France award for KIMMTRAK Treatment for unresectable or metastatic uveal melanoma, a rare and aggressive form of cancer affecting the eye. (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 15 December 2022) Immunocore Holdin
Read more →IMCRImmunocore presents ovarian cancer expansion data for ImmTAC candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers, with vast majority of patients having zero or very low MAGE-A4 expression IMC-C103C ha
Immunocore presents ovarian cancer expansion data for ImmTAC candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers, with vast majority of patients having zero or very low MAGE-A4 expression IMC-C103C has a manageable safety profile and demonstrated signals of
Read more →IMCRImmunocore and Gadeta Announce Agreement to Develop First Gamma Delta ( ) TCR ImmTAC for Solid Tumors Gamma delta TCRs offer potential to address large number of patients without HLA restrictions Agreement combines Gadet
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta ( ) TCR ImmTAC for Solid Tumors Gamma delta TCRs offer potential to address large number of patients without HLA restrictions Agreement combines Gadeta's gamma delta target and TCR identification expertise wi
Read more →IMCRImmunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 November 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel c
Read more →IMCRINDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Profit / Loss and Other Comprehensive Loss for the Three and Nine Months Ended
6-K/Afalse2022-09-3012-31Immunocore Holdings plc0001671927P1M0000000016719272022-01-012022-09-3000016719272021-01-012021-09-3000016719272021-07-012021-09-3000016719272022-07-012022-09-3000016719272021-12-3100016719272022-09-300001671927ifrs-full:ReserveOfCashFlowHedgesMember2020-
Read more →IMCRImmunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting Expression of gp100 protein, the target of KIMMTRAK, is unchanged relative to baseli
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting Expression of gp100 protein, the target of KIMMTRAK, is unchanged relative to baseline in biopsies at time of tumor progression Patients with
Read more →IMCR▲ +6.7%on this newsshared move
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting Expression of gp100 protein, the target of KIMMTRAK, is unchanged relative to baseline in biopsies at time of tumor progression Patients with
Read more →IMCRImmunocore to present at the Jefferies London Healthcare Conference
Immunocore to present at the Jefferies London Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 10 November 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of
Read more →IMCRImmunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update Net KIMMTRAK / tebentafusp revenues of £36.3 million ($40.4 million) in Q3 2022 Promising clinical activity data for IMC-F106C, the first off-the-shelf TCR therapy targeting PRAME, presented at
Read more →IMCR▼ -22.1%on this news
Cautionary Note Regarding Forward Looking Statements This Exhibit contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "can", "will," "bel
Cautionary Note Regarding Forward Looking Statements This Exhibit contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "can", "will," "believe," "expect," "plan," "anticipate," "project" and simil
Read more →IMCR▼ -22.1%on this news
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress Data from Phase 1 dose escalation trial shows IMC-F106C, a PRAME CD3 ImmTAC, activates T ce
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress Data from Phase 1 dose escalation trial shows IMC-F106C, a PRAME CD3 ImmTAC, activates T cells and is well tolerated Durable RECIST responses and red
Read more →IMCRImmunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany, and paid access in France Net KIMMTRAK / tebentafusp revenues of £27.7 million
Read more →IMCRINDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Loss and Other Comprehensive Loss for the Three and Six Months Ended
INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Loss and Other Comprehensive Loss for the Three and Six Months Ended June 30, 2022 and 2021 2 Unaudited Condensed Consolidated Statements of Financial Po
Read more →IMCRImmunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 August 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pi
Read more →IMCRImmunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 Oral presentation in proffered paper session on September 9 at 4:50 PM CEST Four additional poste
Read more →IMCRImmunocore Announces $140 Million Private Placement Financing
Immunocore Announces $140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 July 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering the developme
Read more →IMCRSECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this " Agreement ") is made and entered into as of
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this "Agreement") is made and entered into as of July 15, 2022 (the "Execution Date") by and among Immunocore Holdings plc (registered number 13119746), a public limited company incorporated in England and Wales w
Read more →IMCR▼ -8.3%on this news
Immunocore announces dosing of first patient with ImmTAV bispecific for HIV IMC-M113V, T cell receptor bispecific, targets an HIV Gag antigen Single Ascending Dose portion of Phase 1 study to evaluate safet
Immunocore announces dosing of first patient with ImmTAV bispecific for HIV IMC-M113V, T cell receptor bispecific, targets an HIV Gag antigen Single Ascending Dose portion of Phase 1 study to evaluate safety, antiviral activity, and pharmacokinetics (OXFORDSHIRE, England & CO
Read more →IMCR▼ -8.3%on this news
Immunocore announces dosing of first patient with ImmTAV bispecific for HIV
Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV IMC-M113V, T cell receptor bispecific, targets an HIV Gag antigen Single Ascending Dose portion of Phase 1 study to evaluate safety, antiviral activity, and pharmacokinetics (OXFORDSHIRE, England & CO
Read more →IMCRImmunocore announces the presentation of initial data from the Phase 1 ImmTAV trial for chronic Hepatitis B at the EASL International Liver Congress IMC-I109V, T cell receptor bispecific, targets an envelop
Immunocore announces the presentation of initial data from the Phase 1 ImmTAV trial for chronic Hepatitis B at the EASL International Liver Congress IMC-I109V, T cell receptor bispecific, targets an envelope antigen Single Ascending Dose portion of Phase 1 study to evaluate saf
Read more →IMCRImmunocore announces the presentation of initial data from the Phase 1 ImmTAV trial for chronic Hepatitis B at the EASL International Liver Congress™
Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC-I109V, T cell receptor bispecific, targets an envelope antigen Single Ascending Dose portion of Phase 1 study to evaluate s
Read more →IMCRThe UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK (tebentafusp) for the treatment of unresectable or met
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only treatment approved
Read more →IMCRImmunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commer
Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering the developmen
Read more →IMCRImmunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Tebentafusp and anti-PDL1 show 1 year overall survival (OS) of approximately 75% in heavily
Read more →IMCR▲ +6.1%on this newsshared move
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi's product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK in patients with metastatic cutaneous melanoma Sanofi will eval
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi's product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK in patients with metastatic cutaneous Sanofi will evaluate KIMMTRAK in combination with SAR444245 as part of its ongoing P
Read more →IMCRImmunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Updated overall survival (OS) data from Phase 1b metastatic cutaneous melanoma trial Oral presentation as part of Clinical Science Symposium and two poster presen
Read more →IMCR▼ -12.2%on this news
INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Loss and Other Comprehensive Income for the Three Months Ended
INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Loss and Other Comprehensive Income for the Three Months Ended March 31, 2022 and 2021 2 Unaudited Condensed Consolidated Statements of Financial Positio
Read more →IMCR▼ -12.2%on this news
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved in the United States and European Union for the treatment of unresectable or metastatic uveal melanoma Promotional launches and sales of KIMMTRAK ongoing i
Read more →IMCRImmunocore to present at the 21st Annual Needham Healthcare Conference
Immunocore to present at the 21st Annual Needham Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 7 April 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of
Read more →IMCR▲ +10.6%on this newsshared move
European Commission Approves KIMMTRAK (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only treatment approved in the E.U. to treat patients with unrese
European Commission Approves KIMMTRAK (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only treatment approved in the E.U. to treat patients with unresectable or metastatic uveal melanoma KIMMTRAK demonstrated statistically
Read more →IMCR▲ +6%on this news
Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference
Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 March 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class o
Read more →IMCRImmunocore Reports Full Year 2021 Financial Results and Provides Business Update KIMMTRAK (tebentafusp-tebn) approved by the FDA for the treatment of unresectable or metastatic uveal melanoma; initiated US
Immunocore Reports Full Year 2021 Financial Results and Provides Business Update KIMMTRAK (tebentafusp-tebn) approved by the FDA for the treatment of unresectable or metastatic uveal melanoma; initiated US commercial launch Positive opinion from European Medicines Agency's Com
Read more →IMCRImmunocore Reports Full Year 2021 Financial Results and Provides Business Update
Immunocore Reports Full Year 2021 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved by the FDA for the treatment of unresectable or metastatic uveal melanoma; initiated US commercial launch Positive opinion from European Medicines Agency’s Co
Read more →IMCRImmunocore receives positive CHMP opinion for KIMMTRAK (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma If approved by the European Medicines Agency, KIMMTRAK will be the first and only treatment option approved in Europe to treat patients with unres
Read more →IMCRImmunocore to present at the SVB Leerink Global Healthcare Conference
Immunocore to present at the SVB Leerink Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 February 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class
Read more →IMCR▲ +7.5%on this news
Immunocore announces FDA approval of KIMMTRAK (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only FDA approved therapy for the treatment of unres
Immunocore announces FDA approval of KIMMTRAK (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal KIMMTRAK is the first and only FDA approved therapy for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first T cell receptor (TCR)
Read more →IMCR▲ +7.5%on this news
Immunocore announces FDA approval of KIMMTRAK (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only FDA approved therapy for the treatment of unresectable or metastatic uveal melanoma (mUM) KIMMTRAK is the first T cell
Read more →IMCRImmunocore to present at the 40th Annual J.P. Morgan Healthcare Conference
Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 6 January 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of
Read more →IMCR▲ +13.5%on this news
Immunocore announces initial Phase 1 data of ImmTAC candidate IMC-C103C targeting MAGE-A4 Clinical activity with confirmed durable responses in ovarian cancer and a confirmed durable response in HNSCC Manageable safety p
Immunocore announces initial Phase 1 data of ImmTAC candidate IMC-C103C targeting MAGE-A4 Clinical activity with confirmed durable responses in ovarian cancer and a confirmed durable response in HNSCC Manageable safety profile Biomarkers of T cell activation consistent and rob
Read more →IMCRINDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Loss and Other Comprehensive Income for the Three and Nine Months Ended
INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Loss and Other Comprehensive Income for the Three and Nine Months Ended September 30, 2021 and 2020 2 Unaudited Condensed Consolidated Statements of Financ
Read more →IMCRImmunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update Biologics License Application (BLA) and Marketing Authorisation Application (MAA) submissions accepted for tebentafusp in metastatic uveal melanoma; FDA set a PDUFA date of February 23, 2022 O
Read more →IMCRImmunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
PRESS RELEASE RESS RELEASE Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Tebentafusp in combination with checkpoint inhibitors had acceptable safe
Read more →IMCRImmunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel
Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US and PETACH TIKVAH, Israel, October 18, 2021) -- Immunocore (Nasdaq: IMCR), a late-stag
Read more →IMCRImmunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine
Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine Tebentafusp demonstrated prolonged overall survival (OS) compared to investigator’s choice therapy in previously untreated, metastatic uveal m
Read more →IMCRImmunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial
Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial Linear correlation between the magnitude o
Read more →IMCRImmunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021
Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US 13 September 2021) Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering
Read more →IMCRImmunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma MHRA’s acceptance follows acceptances by the U.S. Food and Drug Administration and European Medicines Age
Read more →IMCR▲ +8.4%on this news
Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma FDA grants Priority Review to tebentafusp for the treatment of HLA-
Read more →IMCR▲ +8.4%on this news
Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Mel
Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma FDA grants Priority Review to tebentafusp for the treatment of HLA
Read more →IMCRImmunocore Reports Second Quarter 2021 Financial Results and Provides Business Update
Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update Biologics License Application (BLA) submission for tebentafusp in metastatic uveal melanoma remains on track for completion in Q3; FDA has granted tebentafusp Real Time Oncology Review (RTOR) a
Read more →IMCRINDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Loss and Other Comprehensive Income for the Three and Six Months Ended
INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Loss and Other Comprehensive Income for the Three and Six Months Ended June 30, 2021 and 2020 2 Unaudited Condensed Consolidated Statements of Financial Po
Read more →IMCRImmunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 June 20
Read more →IMCRImmunocore announces dosing of first patient with ImmTAV bispecific molecule for chronic Hepatitis B
Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B IMC-I109V studied for the treatment of non-cirrhotic HBeAg-negative chronic hepatitis B (HBV) infection (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 Ma
Read more →IMCRImmunocore Reports First Quarter 2021 Financial Results
Immunocore Reports First Quarter 2021 Financial Results Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) is expected to be completed in third quarter of 2021 Launched a global early access program for tebentafusp in metastatic uveal
Read more →IMCRImmunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Overall survival benefit from tebentafusp in patients with best response of progressive disease subject of oral presentation (OXFORDSHIRE, England & CONSHOHOCKEN
Read more →IMCRImmunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting
Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting Tebentafusp is the first investigational therapy to improve Overall Survival (OS) in patie
Read more →IMCRImmunocore Provides Business Update and Reports Full Year 2020 Financial Results
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results Breakthrough Therapy Designation granted by the FDA for tebentafusp in unresectable or metastatic uveal melanoma Tebentafusp Phase 3 randomized trial data subject of an oral presentation at the Am
Read more →IMCRImmunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting
OXFORDSHIRE, England and CONSHOHOCKEN, Penn. and ROCKVILLE, Md., March 10, 2021 (GLOBE NEWSWIRE) -- Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a br
Read more →IMCRImmunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA
OXFORDSHIRE, England and CONSHOHOCKEN, Pa. and ROCKVILLE, Md., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad
Read more →IMCRImmunocore announces key appointments to management and Board
Immunocore announces key appointments to management and Board Ralph Torbay appointed Head of Commercial to spearhead the launch of tebentafusp Dr. Roy S. Herbst appointed as a Non-Executive Director to the Board OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US –
Read more →IMCRImmunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement
Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md
Read more →IMCRImmunocore Announces Pricing of Upsized Initial Public Offering
Immunocore Announces Pricing of Upsized Initial Public Offering OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 4 February 2021 – Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell re
Read more →IMCRImmunocore announces closing of $75.0 Million Series C round
Immunocore announces closing of $75.0 Million Series C round Funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 January 2021) Immunocore, a
Read more →IMCRImmunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020
Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 December 2020) Immunocore (or the “Company”), a late-stage biotechnology company pioneering the development
Read more →IMCRImmunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma
Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma The primary endpoint of Overall Survival favored tebentafusp with a Hazard Ratio = 0.51 (
Read more →IMCRImmunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy
Immunocore appoints Brian Di Donato as Chief Financial Officer and (OXFORD, England & CONSHOHOCKEN, Pa. & ROCKVILLE, Md., 6 May 2020) Immunocore, a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transform
Read more →IMCRImmunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech First-in-human clinical trial of IMC-C103C scheduled to commence in 2019 in multiple solid tumour indications (Oxford, UK and Conshohocken, US, 19 November 2018) Immunocore Limited, a
Read more →IMCRImmunocore strengthens IP position in the field of TCR-based therapeutics
Immunocore strengthens IP position in the field of TCR-based therapeutics Notice of Allowance received from US patent and trademark office relating to ImmTAC® platform (Oxford, UK and Conshohocken, US, 5 September 2018) Immunocore Limited, a leading T Cell Receptor (TCR) biotec
Read more →IMCRImmunocore Announces Start of Phase I ImmTAC Study in Patients with Solid Tumours
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours Study of IMCnyeso in NSCLC, Bladder Cancer, Melanoma and Synovial Sarcoma is the first in GSK collaboration (Oxford, UK and Conshohocken, US, 20 August 2018) Immunocore Limited, a leading T Cell
Read more →Competitive Position
How IMCR ranks across every disease it competes inCompetitive Position is a premium feature
See how IMCR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial